An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas

Cancer Research

Volumn 62, Issue 11, 2002, Pages 3167-3174

  Melero, Ignacio ^a   Gabari, Izaskun ^a   Mazzolini, Gùillermo ^a   Schmitz, Volker ^a   Rodriguez Calvillo, Mercedes ^a   Tirapu, Iñigo ^a   Prieto, Jesús ^a   Camafeita, Emilio ^b   Albar, Juan P ^b   Corbí, Angel L ^c   Relloso, Miguel ^c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b CSIC   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 2; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL ADHESION; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; DENDRITIC CELLS; ENDOTHELIUM; FEMALE; HUMANS; LECTINS; LECTINS, C-TYPE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; RECEPTORS, CELL SURFACE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 0036606328     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Monoclonal antibody therapy for solid tumors
2. Enhancement of antitumor immunity by CTLA-4 blockade
3. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
4. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
5. Antiintegrin α β blocks human breast cancer growth and angiogenesis in human skin
6. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
7. Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1
8. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1
9. Characterization of murine intercellular adhesion molecule-2
10. DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking
11. DC-SIGN, a dendritic cell-specific HIV-1binding protein that enhances trans-infection of T cells
12. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses
13. DC-SIGN and LFA-1: A battle for a ligand
14. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR: Subunit organization and binding to multivalent ligands
15. The immunological synapse
16. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN
17. Prolonged eosinophil accumulation in allergic lung interstitium of ICAM-2 deficient mice results in extended hyperresponsiveness
18. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas
19. Isolation and characterization of an established endothelial cell line from transgenic mouse hemangiomas
20. Murine endothelioma cell lines transformed by polyoma middle T oncogene as target for and producers of cytokines
21. Immortalized dendritic cell line fully competent in antigen presentation initiates primary T cell responses in vivo
22. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
23. DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGFβ and anti-inflammatory agents
24. Thrombopenic purpura induced by a monoclonal antibody directed to a 35-kilodalton surface protein (p35) expressed on murine platelets and endothelial cells
25. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12. Results in marked antitumoral synergy
26. Signaling through the LFA-1 leucocyte integrin actively regulates intercellular adhesion and tumor necrosis factor-α production in natural killer cells
27. The SCID but not the RAG-2 gene product is required for S μ-S epsilon heavy chain class switching
28. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
29. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12
30. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level
31. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
32. Cross-linking of intercellular adhesion molecule 1 (CD54) induces AP-1 activation and IL-1β transcription
33. Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in β 1 and β 2 integrin function
34. VCAM-1 activates phosphatidylinositol 3-kinase and induces p120Cbl phosphorylation in human airway smooth muscle cells
35. Association of ezrin with intercellular adhesion molecule-1 and -2 (ICAM-1 and ICAM-2). Regulation by phosphatidylinositol 4. 5-bisphosphate
36. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2
37. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4
38. Antitumor effect of locally produced CD95 ligand
39. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL)
40. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance